Last reviewed · How we verify

CS1001 monoclonal antibody

CStone Pharmaceuticals · Phase 3 active Biologic

CS1001 is a monoclonal antibody that blocks PD-L1, preventing its interaction with PD-1 and PD-L2 receptors to enhance anti-tumor immune responses.

CS1001 is a monoclonal antibody that blocks PD-L1, preventing its interaction with PD-1 and PD-L2 receptors to enhance anti-tumor immune responses. Used for Non-small cell lung cancer, Gastric cancer, Esophageal cancer.

At a glance

Generic nameCS1001 monoclonal antibody
SponsorCStone Pharmaceuticals
Drug classPD-L1 inhibitor
TargetPD-L1
ModalityBiologic
Therapeutic areaOncology
PhasePhase 3

Mechanism of action

CS1001 binds to programmed death ligand 1 (PD-L1) on tumor cells and immune cells, blocking the inhibitory PD-L1/PD-1 axis that tumors exploit to evade immune surveillance. By disrupting this checkpoint interaction, the antibody restores T-cell activation and proliferation, enabling the immune system to recognize and eliminate cancer cells. This mechanism is characteristic of immune checkpoint inhibitors used across multiple solid and hematologic malignancies.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: